Novabridge Biosciences ADR
NBP4.020USD
-0.160-3.83%
Close 12/08, 16:00（ET）Quotes delayed by 15 min
--Market Cap
LossP/E TTM
More Details of Company
Novabridge Biosciences ADR Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Novabridge Biosciences ADR
Name
Name/Position
Position
Shareholding
Change
Mr. Wei Fu
Mr. Wei Fu
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kyler Lei
Mr. Kyler Lei
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Claire Xu
Mr. Claire Xu
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Robert Lenz, M.D., Ph.D.
Dr. Robert Lenz, M.D., Ph.D.
Independent Director
Independent Director
--
--
,
,
Independent Director
Independent Director
--
--
Dr. Phillip Dennis, M.D., Ph.D.
Dr. Phillip Dennis, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chia-Hung (Conor) Yang
Mr. Chia-Hung (Conor) Yang
Independent Director
Independent Director
--
--
Dr. Xi-Yong (Sean) Fu, Ph.D.
Dr. Xi-Yong (Sean) Fu, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chun Kwok (Alan) Au
Mr. Chun Kwok (Alan) Au
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Wei Fu
Mr. Wei Fu
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kyler Lei
Mr. Kyler Lei
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Claire Xu
Mr. Claire Xu
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Robert Lenz, M.D., Ph.D.
Dr. Robert Lenz, M.D., Ph.D.
Independent Director
Independent Director
--
--
,
,
Independent Director
Independent Director
--
--
Dr. Phillip Dennis, M.D., Ph.D.
Dr. Phillip Dennis, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
China (Mainland)
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: 5 hours ago
Updated: 5 hours ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
102
43.88M
38.07%
+9.43M
2025Q3
118
43.87M
38.07%
+959.09K
2025Q2
118
26.13M
31.79%
-13.78M
2025Q1
122
24.15M
29.39%
-18.93M
2024Q4
134
22.41M
27.40%
-20.19M
2024Q3
146
29.96M
36.94%
-20.28M
2024Q2
191
30.91M
38.11%
-23.68M
2024Q1
262
28.58M
35.04%
-19.41M
2023Q4
293
28.92M
35.46%
-21.29M
2023Q3
326
39.77M
48.22%
-7.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
Related ETFs
Updated: 5 hours ago
Updated: 5 hours ago
Name
Proportion
ALPS Barron's 400 ETF
0.23%
SPDR S&P Emerging Markets Small Cap ETF
0.03%
SPDR S&P China ETF
0.01%
SPDR Portfolio Emerging Markets ETF
0.01%
ActivePassive International Equity ETF
0%
Avantis Emerging Markets Small Cap Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Invesco Golden Dragon China ETF
0%
SPDR S&P Emerging Asia Pacific ETF
0%
ALPS Barron's 400 ETF
Proportion0.23%
SPDR S&P Emerging Markets Small Cap ETF
Proportion0.03%
SPDR S&P China ETF
Proportion0.01%
SPDR Portfolio Emerging Markets ETF
Proportion0.01%
ActivePassive International Equity ETF
Proportion0%
Avantis Emerging Markets Small Cap Equity ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Invesco Golden Dragon China ETF
Proportion0%
SPDR S&P Emerging Asia Pacific ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Novabridge Biosciences ADR?
The top five shareholders of Novabridge Biosciences ADR are:
What are the top three shareholder types of Novabridge Biosciences ADR?
The top three shareholder types of Novabridge Biosciences ADR are:
Other
Other
How many institutions hold shares of Novabridge Biosciences ADR (NBP)?
As of 2025Q4, 102 institutions hold shares of Novabridge Biosciences ADR, with a combined market value of approximately 43.88M, accounting for 38.07% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.00%.
What is the biggest source of revenue for Novabridge Biosciences ADR?
In FY2024, the -- business generated the highest revenue for Novabridge Biosciences ADR, amounting to -- and accounting for --% of total revenue.
